2022
The impact of race and ethnicity on outcomes of patients with myelodysplastic syndromes: a population-based analysis
Goksu SY, Ozer M, Goksu BB, Wang R, Khatib J, Patel PA, Vusirikala M, Cole S, Seyhanli A, Collins RH, Chung S, Zeidan AM, Madanat YF. The impact of race and ethnicity on outcomes of patients with myelodysplastic syndromes: a population-based analysis. Leukemia & Lymphoma 2022, 63: 1651-1659. PMID: 35133215, DOI: 10.1080/10428194.2022.2032034.Peer-Reviewed Original ResearchConceptsIncidence rate ratiosNon-Hispanic whitesMyelodysplastic syndromeRace/ethnicityNHB patientsNon-Hispanic blacksSurvival outcomesDisease characteristicsAge groupsHigher incidence rate ratioLower incidence rate ratiosOutcomes of patientsBetter overall survivalPopulation-based analysisAcute myeloid leukemiaNHW patientsAdult patientsOverall survivalSEER databaseClinical outcomesIncidence rateMyeloid leukemiaPatientsEthnic backgroundDisease risk
2020
Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
Zeidan AM, Wang R, Wang X, Shallis RM, Podoltsev NA, Bewersdorf JP, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Advances 2020, 4: 2192-2201. PMID: 32433746, PMCID: PMC7252544, DOI: 10.1182/bloodadvances.2020001779.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaDecitabine-treated patientsTransfusion independenceRed blood cell transfusion independenceLarge population-based studyOlder AML patientsRBC transfusion independenceEnd Results-MedicarePopulation-based studyStandard of careAgent azacitidineMedian survivalOlder patientsIntensive therapyAML patientsClinical outcomesClinical benefitMyeloid leukemiaMortality riskPatientsAzacitidineDecitabineOlder adultsOne-thirdMeaningful differences